<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02572713</url>
  </required_header>
  <id_info>
    <org_study_id>S4-001</org_study_id>
    <nct_id>NCT02572713</nct_id>
  </id_info>
  <brief_title>Systemic Synuclein Sampling Study (S4)</brief_title>
  <acronym>S4</acronym>
  <official_title>Systemic Synuclein Sampling Study (S4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Banner Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paracelsus Elena Klinik</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Michael J. Fox Foundation for Parkinson's Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure alpha-synuclein in peripheral body tissues and fluids&#xD;
      in Parkinson's disease (PD). This may help in developing better treatments for PD patients in&#xD;
      the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, cross-sectional, observational study to evaluate α-syn pathology in&#xD;
      multiple tissues and biofluids in individual subjects with PD and HC at a single time point.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">August 1, 2017</completion_date>
  <primary_completion_date type="Actual">August 1, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>α-syn levels in blood</measure>
    <time_frame>24 months</time_frame>
    <description>Blood will be analyzed using the most optimal, currently available, quantitative assays. The outcome will be expressed as a concentration of α-syn levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>α-syn levels in saliva</measure>
    <time_frame>24 months</time_frame>
    <description>Saliva will be analyzed using the most optimal, currently available, quantitative assays. The outcome will be expressed as a concentration of α-syn levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>α-syn levels in CSF</measure>
    <time_frame>24 months</time_frame>
    <description>CSF will be analyzed using the most optimal, currently available, quantitative assays. The outcome will be expressed as a concentration of α-syn levels.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>α-syn deposits in skin</measure>
    <time_frame>24 months</time_frame>
    <description>α-syn burden in skin biopsies will be expressed as 1) simply positive or negative, i.e. whether any two slides are positive out of all examined 2) by total percentage of slides examined that are positive 3) by site of highest density of positive α-syn fibers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>α-syn deposits in submandibular gland</measure>
    <time_frame>24 months</time_frame>
    <description>α-syn burden in the submandibular tissue will be expressed as 1) simply positive or negative, i.e. whether any two slides are positive out of all examined 2) by total percentage of slides examined that are positive 3) by site of highest density of positive α-syn fibers.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>α-syn deposits in colon</measure>
    <time_frame>24 months</time_frame>
    <description>α-syn burden in the colon tissue will be expressed as 1) simply positive or negative, i.e. whether any two slides are positive out of all examined 2) by total percentage of slides examined that are positive 3) by site of highest density of positive α-syn fibers.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Early PD</arm_group_label>
    <description>20 early PD not requiring dopamine replacement therapy have been enrolled.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate PD</arm_group_label>
    <description>20 moderate PD on dopamine replacement therapy without motor fluctuations have been enrolled.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced PD</arm_group_label>
    <description>21 advanced PD with motor fluctuations have been enrolled.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>21 healthy controls have been enrolled.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biofluid samplings</intervention_name>
    <description>Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)</description>
    <arm_group_label>Advanced PD</arm_group_label>
    <arm_group_label>Early PD</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Moderate PD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Tissue samplings</intervention_name>
    <description>Tissue samplings (skin, colon, submandibular gland)</description>
    <arm_group_label>Advanced PD</arm_group_label>
    <arm_group_label>Early PD</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Moderate PD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DaTSCAN™</intervention_name>
    <arm_group_label>Advanced PD</arm_group_label>
    <arm_group_label>Early PD</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Moderate PD</arm_group_label>
    <other_name>ioflupane-123I</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biofluid samplings [blood, saliva, and cerebrospinal fluid (CSF)] Tissue samplings (skin,&#xD;
      colon, submandibular gland)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited through patient care clinics, physician referrals, and by&#xD;
        reaching out to the community (e.g. PD-affiliated groups).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (PD subjects):&#xD;
&#xD;
          -  Male or female age 40 or older at the time of PD diagnosis.&#xD;
&#xD;
          -  Clinical diagnosis of PD based on bradykinesia plus one of the following: rest tremor&#xD;
             or rigidity.&#xD;
&#xD;
          -  DAT deficit at screening based on visual interpretation of DaTSCAN™ imaging.&#xD;
&#xD;
          -  PD subjects will need to fall into one of the following stages:&#xD;
&#xD;
               -  Early untreated PD not requiring dopamine replacement medication&#xD;
                  (anticholinergics, MAO-B inhibitors and amantadine permitted), Hoehn and Yahr&#xD;
                  1-2, &lt; 2 years from diagnosis.&#xD;
&#xD;
               -  Moderate PD responsive and currently treated with dopamine replacement therapy&#xD;
                  without evidence of motor fluctuations or dyskinesias.&#xD;
&#xD;
               -  Advanced PD with motor fluctuations or dyskinesias, &gt; 5 years from diagnosis.&#xD;
&#xD;
          -  Ability to provide written informed consent in accordance with Good Clinical Practice&#xD;
             (GCP), International Conference on Harmonization (ICH), and local regulations.&#xD;
&#xD;
          -  Willing and able to comply with scheduled visits, required study procedures and&#xD;
             laboratory tests.&#xD;
&#xD;
        Inclusion Criteria (HC subjects):&#xD;
&#xD;
          -  Male or female age 50 or older at the time of the screening visit&#xD;
&#xD;
          -  Ability to provide written informed consent in accordance with Good Clinical Practice&#xD;
             (GCP), International Conference on Harmonization (ICH), and local regulations.&#xD;
&#xD;
          -  Willing and able to comply with scheduled visits, required study procedures and&#xD;
             laboratory tests.&#xD;
&#xD;
        Exclusion Criteria (all subjects):&#xD;
&#xD;
          -  Has a history of cancer (other than basal and squamous cell skin cancers), autoimmune&#xD;
             disorder, liver disease, or other hematological disorder within the past 5 years.&#xD;
&#xD;
          -  Current treatment with anticoagulants (e.g., Coumadin, heparin) that would preclude&#xD;
             safe completion of the lumbar puncture (LP) and tissue biopsy procedures.&#xD;
&#xD;
          -  Current treatment with an antiplatelet agent (Plavix or aspirin &gt;325 mg/day).&#xD;
&#xD;
          -  Has a diagnosis of diabetes mellitus requiring either an oral agent or insulin&#xD;
             therapy.&#xD;
&#xD;
          -  A bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia.&#xD;
&#xD;
          -  Has received botulinum toxin injections to the submandibular gland within the past&#xD;
             year.&#xD;
&#xD;
          -  Has a condition that precludes safe performance of routine LP, such as prohibitive&#xD;
             lumbar spinal disease.&#xD;
&#xD;
          -  Has a condition that precludes the safe performance of the flexible sigmoidoscopy&#xD;
             procedure or may interfere with obtaining evaluable colonic tissue biopsies, including&#xD;
             a prior colonoscopy with significant findings (e.g. polyp with a positive finding,&#xD;
             ulcerative colitis, Crohn's disease, inflammatory disease).&#xD;
&#xD;
          -  Has a condition that precludes the safe performance of the submandibular gland&#xD;
             procedure or may interfere with obtaining evaluable submandibular tissue biopsies,&#xD;
             including any previous or active significant disease affecting the submandibular gland&#xD;
             (e.g. inflammatory disease, infection, tumor).&#xD;
&#xD;
          -  Has a condition that precludes the safe performance of the skin punch biopsy procedure&#xD;
             or may interfere with obtaining evaluable skin tissue biopsies, including any previous&#xD;
             or active significant dermatological disease (e.g. previous biopsy with any of the&#xD;
             following findings: inflammatory disease, scar tissue, psoriasis, keloid formation,&#xD;
             skin cancer).&#xD;
&#xD;
          -  Any other medical or psychiatric condition or laboratory abnormality, which in the&#xD;
             opinion of the Site Investigator would preclude participation.&#xD;
&#xD;
          -  Use of investigational drugs or devices within 30 days prior to the screening visit.&#xD;
&#xD;
        Exclusion criteria (PD subjects):&#xD;
&#xD;
          -  Has other significant neurological disorders (clinically significant stroke, brain&#xD;
             tumor, hydrocephalus, epilepsy, other neurodegenerative disorders, encephalitis,&#xD;
             repeated head trauma, polyneuropathy).&#xD;
&#xD;
          -  Has significant autonomic dysfunction (symptomatic orthostasis, hypotension or urinary&#xD;
             incontinence) suggestive of an atypical parkinsonism.&#xD;
&#xD;
          -  Has atypical features of parkinsonism including but not limited to supranuclear gaze&#xD;
             palsy, early recurrent falls, corticospinal track abnormalities, cerebellar&#xD;
             abnormalities, significant cognitive dysfunction.&#xD;
&#xD;
        Exclusion criteria (HC subjects):&#xD;
&#xD;
          -  Has a family history of PD in any first-degree relative.&#xD;
&#xD;
          -  Has a significant neurological disorder (a neurodegenerative condition, clinically&#xD;
             significant stroke, brain tumor, hydrocephalus, epilepsy, other neurodegenerative&#xD;
             disorders, encephalitis, repeated head trauma, polyneuropathy).&#xD;
&#xD;
          -  Has a Montreal Cognitive Assessment (MoCA) score of less than 26.&#xD;
&#xD;
          -  Has a diagnosis of REM sleep behavior disorder.&#xD;
&#xD;
          -  Has a primary dystonia, restless legs syndrome, essential tremor, or other movement&#xD;
             disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lana Chahine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital Movement Disorders Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Lana Chahine, MD</investigator_full_name>
    <investigator_title>Clinical Co-PI</investigator_title>
  </responsible_party>
  <keyword>Parkinson's Disease</keyword>
  <keyword>alpha-synuclein</keyword>
  <keyword>biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

